Furthermore, since it has been reported that CLL cells may impose metabolic alterations on CD4+ T cells [60], we can hypothesize that OXPHOS inhibition might lead to the improvement of T-cell based therapies. Here, CD4 is linked to B-cell chronic lymphocytic leukemia.